Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Hengrui Innovative Drug Sudi Insulin Noliglutide Injection for Adults with Type 2 Diabetes Listed for Application Acceptance
Recently, Hengrui Medicine received the “Acceptance Notice” issued by the National Medical Products Administration. The company’s Class 1 innovative drug, long-acting basal insulin analog/GLP-1 receptor agonist fixed-dose combination product, Shude Insulin Noli Peptide Injection, has been accepted for its drug listing application. The proposed indication is: for adult patients with type 2 diabetes mellitus who have poor blood sugar control, to improve blood sugar levels through combined use with other oral hypoglycemic agents based on diet and exercise. (Hengrui Medicine)